Cuts in funding at Wellcome

Due to the tough times, the EU's largest biomedical research charity, the Wellcome Trust, has lost £2 billion in assets, and is therefore cutting its funding for grants by £30 million. Wellcome Trust's Gibbs BuildingIn linkurl:a statement,;http://www.wellcome.ac.uk/News/2009/News/WTX053144.htm the charity announced: "Over the next financial year we will commit around £590 million to support biomedical research in the UK and internationally, as compared to £620 million in 200

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Due to the tough times, the EU's largest biomedical research charity, the Wellcome Trust, has lost £2 billion in assets, and is therefore cutting its funding for grants by £30 million.
Wellcome Trust's Gibbs Building
In linkurl:a statement,;http://www.wellcome.ac.uk/News/2009/News/WTX053144.htm the charity announced: "Over the next financial year we will commit around £590 million to support biomedical research in the UK and internationally, as compared to £620 million in 2007/08." The charity says it will also continue to fund large-scale "strategic" projects. Wellcome's asset base has shrunk from £15.1 billion to £13.1 billion. This belt-tightening will undoubtedly steepen competition for funding, reported linkurl:Science Business.;http://bulletin.sciencebusiness.net/ebulletins/showissue.php3?page=/548/3248/12815 In response, the Trust said it will "continue to prioritise funding the brightest people and the best ideas." Image courtesy of Wikipedia.
**__Related stories:__***linkurl:How to spend the NIH stimulus;http://www.the-scientist.com/blog/display/55413/
[11th February 2009]*linkurl:NIH boost passed in Senate;http://www.the-scientist.com/blog/display/55411/
[10th February 2009]*linkurl: London gets new neuro institute;http://www.the-scientist.com/blog/display/54941/
[21st August 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies